Ningke Biotech announced that on September 17, 2025, the Shizuishan Intermediate Court decided to accept the company restructuring case. On November 7, the funders' group meeting and the first creditors' meeting voted separately to pass the funders' rights adjustment plan and the restructuring plan; on November 13, the court ruled to approve the restructuring plan and terminate the restructuring process. As of December 30, the restructuring investors paid the total investment consideration of 1,241 billion yuan, bankruptcy expenses, cash settlement payments or withdrawals, debt-loss stock allocations or deposits, additional stock transfers, service trusts were established, and the “Delivery Confirmation” came into effect, and the implementation of the restructuring plan was completed.

Ningke Biotech announced that on September 17, 2025, the Shizuishan Intermediate Court decided to accept the company restructuring case. On November 7, the funders' group meeting and the first creditors' meeting voted separately to pass the funders' rights adjustment plan and the restructuring plan; on November 13, the court ruled to approve the restructuring plan and terminate the restructuring process. As of December 30, the restructuring investors paid the total investment consideration of 1,241 billion yuan, bankruptcy expenses, cash settlement payments or withdrawals, debt-loss stock allocations or deposits, additional stock transfers, service trusts were established, and the “Delivery Confirmation” came into effect, and the implementation of the restructuring plan was completed.